CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 350 enrolled
Drug / intervention
Olanzapine or amisulpridedrug
Likely dose
Olanzapine or amisulpride 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01029769
NCT01029769N/ACompleted
CompareCT.gov

The Switch Study - Efficacy of Early Antipsychotic Switch Versus Maintenance in Patients With Schizophrenia Poorly Responding to Two Weeks of Antipsychotic Treatment

Technical University of Munich·interventional·Posted Dec 10, 2009·Updated Oct 21, 2024

In Brief

A clinical study evaluating Olanzapine or amisulpride for Schizophrenia and 2 related conditions. Completed, enrolled 350 participants across 1 site.

Detailed Summary

The main aim of the trial is to study whether a change of medication in non-responders to a two-weeks antipsychotic drug trial is more effective than continued treatment with the same antipsychotic. Hypothesis: Non-responders who are switched at 2 weeks to another antipsychotic are more frequently in symptomatic remission at week 8 than non-responders who stay on the same antipsychotic

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2009
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2014
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.6 years ago

Interventions

Olanzapine or amisulpridedrug

Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding